Grey Matters Health Inc · CSE:GREY
Grey Matters Health — Algernon Pharmaceuticals — IPO Roadshow (May 2022)
24 slides from Grey Matters Health's IPO roadshow presentation, May 10, 2022
Slide 1: Issuer Free Writing Prospectus
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-262878 Relating to Preliminary Prospectus dated May 9, 2022 ALGERNON > PHARMACEUTICALS CSE:AGN | OTCQB:AGNPF | XFRA:AGWO
Slide 2: Disclaimer
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-262878 Relating to Preliminary Prospectus dated May 9, 2022 DISCLAIMER Certain statements in this presentation (the "Presentation") are forward-looking statements, which are made as of the date of this Presentat
Slide 3: Development of Novel Drug Treatments
DEVELOPMENT OF NOVEL DRUG TREATMENTS Algernon potentially reduces corporate risk by having several chemically distinct Phase-2-Ready compounds selected using the following criteria: Safety REPURPOSED LEAD Investigating already approved Drugs Reduce COMPOUNDS Risk of Study Failure From Safety Issues
Slide 4: Algernon Pharmaceuticals Lead Drug Candidates
ALGERNON PHARMACEUTICALS LEAD DRUG CANDIDATES ‘CLINICAL PIPELINE ‘CANDIDATE INDICATION DEVELOPMENT STAGE [recumca. | |paase]——emase 2] PmASES || REULATORY RENEW Inflamn Phase 2 Pilot Study Ongoing Data - 2, 2022 p Chronic Kidney Disease Began CGMP Manufacturing - Q1, 2022 Begin Phase 1 - Q4, 2022 ne
Slide 5: Upcoming Milestones
UPCOMING MILESTONES IPF / COUGH DMT / STROKE DMT / STROKE Final Data from IPF / Cough Study Begin Phase 1 Study Phase I DMT Stroke Data Q12022 Q2 2022 Q3 2022 Q4 2022 Q12023 CKD CKD Began Repirinast CGMP Begin Phase 1 CKD Study manufacturing ALGERNON } 7
Slide 6: Lead Drug: NP-120 (Ifenprodil)
BX, ALGERNON > LEAD DRUG: NP-120 (IFENPRODIL) Pi Exis Our Current Sales / Market Indications Indications Therapies Size Idiopathic Pulmonary Fibrosis + Peripheral Arterial Obstructive Disease (France until 2015) + Vertigo (Japan | South Korea) » Phase 2 {2} Seestenanientecoenatrane Ofev (Nintedanib)
Slide 7: Mechanism of Action - Cough
MECHANISM OF ACTION - COUGH CLINICAL CANDIDATES CNS Receptors ous condicote® Acting on Control Urge Ld to Cough * Ifenprodil (Algernon) > NMDAR Antagonist Drug Candidates Acting on Nerves in Lung/Airway Tissue * Gefapixant (Merck) + BLU-5937 (Bellus) > Both P2X3R Antagonists ALGERNON >
Slide 8: IPF - Bleomycin Animal Study
IPF - BLEOMYCIN ANIMAL STUDY FIBROSIS + N=10/Arm REDUCTION(TRICHROME) + Treatment Day 7-21 * Clinically Relevant Doses 55.3% p=0015 © 43.9% p=NS v IFENPRODIL PIRFENIDONE NINTEDANIB (amaleg) TID (lo0mg/kg) BID (eomelke) OD ALGERNON } 10
Slide 9: Acute Cough - Citric Acid Model Study
ACUTE COUGH - CITRIC ACID MODEL STUDY 40 + Acute Guinea Pig Citric Acid Model + (n=6/arm) Using Clinically Relevant Doses of enprodil and Gefapixant Data — Cough Count Mean Cough Count + Ifenprodil = 42% Reduction (p < 0.01) + Gefapixantt = 20% Reduction (p < 0.05) Unlike Gefapixant, Ifenprodil Has
Slide 10: Acute Cough - Citric Acid Model Study
ACUTE COUGH - CITRIC ACID MODEL STUDY $ 80 6 * 60 Ss é Data — Onset of First Cough (Seconds) 2” ° + Ifenprodil = 75% Delay (p < 0.05) op = * Gefapixant = 45% Delay (p = NS) § = 0 > £ dS O Pe 8 WD OD *p<0.05 compared to placebo eg & SS s & ss ge ev S ee ALGERNON 12
Slide 11: Phase 2 Clinical Trial in IPF & Chronic Cough
PHASE 2 CLINICAL TRIAL IN IPF & CHRONIC COUGH + 20 Patient Open-Label IPF Patients With Cough + 12Weeks of Treatment, 20 mg lfenprodil 3 x per day + Endpoints: ¥ Primary for Cough: Reduction in 24-hour and Waking Cough Counts vs. Baseline, Measured by Ambulatory Cough Monitor Primary for Lung Functi
Slide 12: Phase 2 Clinical Trial in Chronic Cough Interim Data
PHASE 2 CLINICALTRIAL IN CHRONIC COUGH INTERIM DATA + Interim Data Announced September 20, 2021 Showed a Trend to a Relative Reduction in Cough Count When Compared To Baseline Measurement Control + Patients 24-Hour Total and Waking Cough Counts Were Measured Using an Ambulatory Cough Monitor at Base
Slide 13: Public Company Comparables for Chronic Cough & IPF
PUBLIC COMPANY COMPARABLES FOR CHRONIC COUGH & IPF re) Bellus treyi — ALGERNO TSX:BLU free Naspag:sLu_NASDAQ:TRVI sania Market Cap: $691.4 $125.5") $7.1 Debt: $0.9 $146 $0.0 LT™M Rev: $0.0 $0.0 $0.0 Indication: Chronic Cough Chronic Cough Chronic Cough Clinical Phase: Phase 2b Phase 2 Phase 2 Premiu
Slide 14: AP-188 (N,N-Dimethyltryptamine) DMT
AP-188 (N,N-DIMETHYLTRYPTAMINE) DMT Current Sales / Market Therapies ize ALGERNON 5 (ES + Tissue Plasminogen + Global Stroke Activator (“TPA”) ‘Treatment Market is Expected to Reach a + Surgical removal of Value Of ~ US$ 15 B blockage by the Year 2027") (“thrombectomy”) + Range of 2% - 10% globally
Slide 15: DMT Stroke Program
DMT STROKE PROGRAM Preclinical Data + InVitro Research Shows DMT has Neuroplastic and Neurogenesis Effects in Cortical Neuron Assay” * Research Confirms Sub-psychedelic Dose Active in Depression and Anxiety Model® + DMT was Effective in an Animal Stroke Study) © Olsen inviro study: Cell Reports (201
Slide 16: Clinical Programs - Overview
CLINICAL PROGRAMS - OVERVIEW DMT PROMOTES NEUROGENESIS AND SYNAPTIC GROWTH \ veH oa . omr j bso tO Oe 4 —po 4 —or 4 — .so a 12 —VEH 42. —VEH 42 — VEH 5 10 10: 10: $s * 8 Be 6 6 24 4 ‘ 22 2 2 0. 0 ot 0 20 40 60 8 = 0-20 40 60 80 Distance from Center (um) Distance from Center (ym) (19 Olsen in vitro s
Slide 17: DMT Stroke Program
DMT STROKE PROGRAM IP Filed for New Forms of DMT, Dosing, Formulation, Method of Use and Combination Therapy for Stroke Rehabilitation cGMP Synthesis of DMT Active Pharmaceutical Ingredient (API) Complete - Dalton Pharma Services Preclinical Work Completed - Charles River Labs The Company filed for
Slide 18: NP-251 (Repirinast) Indications
Indications + Sold for 25 years in Japan under Romet™ for Asthma + Pediatric formulation approved in 1990 (1) pele aneepencmarersacch concn sehen! NP-251 (REPIRINAST) ALGERNON > + Focus on managing . symptoms and complications that include high blood pressure, swelling and anemia Current Sales / Mar
Slide 19: Chronic Kidney Disease - UUO Model Study
CHRONIC KIDNEY DISEASE - UUO MODEL STUDY 2 UNILATERAL URETER OBSTRUCTION MODEL + N=10/Arm + Start Treatment Day 0-14 + Post Bonferroni Corrected + Reduction in Fibrosis vs Negative Control + Once a Day (QD) Treatment + Clinically Relevant Doses + Independent 3 Party Stats Review + CVC = Cenicriviroc
Slide 20: Balance Sheet & Capitalization
BALANCE SHEET & CAPITALIZATION As of February 28, 2022 Cash $1.8M Debt - Common Stock 1,674,868 Warrants (WAEP $44.54) 372,020 Options (WAEP $1 1.02) 155,750 Total Fully Diluted 2,202,638 ALGERNON 2
Slide 21: Use of Proceeds
USE OF PROCEEDS Description of Use Estimated Amount of Net Proceeds General and Administrative Expenses (18 months) US$ 1,500,000 IPF/Chronic Cough - Ifenprodil Phase 2 (Australia) Us$500,000 Stroke - DMT + Phasel.. US$2,500,000 CKD - Repirinast Preclinical... US$ 1,000,000 Phase I... US$ 1,000,000
Slide 22: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Christopher J.Moreau CHIEF EXECUTIVE OFFICER President. CEO & director of a TSX listed R&D company in the fe sciences sector for ‘over nine years Experienced with startups, licensing, mergers & acquisitions, and ineegration ‘Over 30 years of Senior Management ‘experience
Slide 23: Medical and Scientific Advisors
MEDICAL AND SCIENTIFIC ADVISORS Algernon Medical & Scientific Advisory Board Chronic Cough Dr. Mark Swaim, MD, PhD Dr. Jacky Smith, MB, ChB, FRCP, PhD Dr. Martin Kolb MD, PhD Idiopathic Pulmonary Fibrosis Dr. Martin Kolb MD, PhD Pancreatic & Small Cell Lung Cancer Dr. William North PhD Dr. Konstanti
Slide 24: Algernon Pharmaceuticals
3 ALGERNON > CSE:AGN | OTCQB:AGNPF | XFRA:AGWO 7